Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,374.00 | 82.20 | -0.97% |
| CAC 40 | 7,727.93 | 42.55 | -0.55% |
| DAX 40 | 23,344.54 | 257.89 | 1.12% |
| Dow JONES (US) | 41,411.81 | 94.38 | 0.23% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,893.05 | 84.68 | -0.47% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.25 | 93.36 | 0.76% |
| S&P 500 | 5,671.25 | 15.42 | -0.27% |
| S&P/ASX 200 | 8,157.80 | 80.20 | -0.97% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |